GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (STU:TPM0) » Definitions » Cyclically Adjusted FCF per Share

Tonix Pharmaceuticals Holding (STU:TPM0) Cyclically Adjusted FCF per Share : €-636,550.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Tonix Pharmaceuticals Holding Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Tonix Pharmaceuticals Holding's adjusted free cash flow per share for the three months ended in Mar. 2024 was €-6.438. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-636,550.00 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 10.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Tonix Pharmaceuticals Holding was 23.90% per year. The lowest was 10.90% per year. And the median was 17.10% per year.

As of today (2024-06-08), Tonix Pharmaceuticals Holding's current stock price is €90.24. Tonix Pharmaceuticals Holding's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 was €-636,550.00. Tonix Pharmaceuticals Holding's Cyclically Adjusted Price-to-FCF of today is .


Tonix Pharmaceuticals Holding Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Cyclically Adjusted FCF per Share Chart

Tonix Pharmaceuticals Holding Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -63,532.00 -46,809.90 -46,039.10 -37,433.90 -298,149.00

Tonix Pharmaceuticals Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -42,380.70 -81,027.60 -228,835.00 -298,149.00 -636,550.00

Competitive Comparison of Tonix Pharmaceuticals Holding's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tonix Pharmaceuticals Holding's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Cyclically Adjusted Price-to-FCF falls into.



Tonix Pharmaceuticals Holding Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Tonix Pharmaceuticals Holding's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-6.438/131.7762*131.7762
=-6.438

Current CPI (Mar. 2024) = 131.7762.

Tonix Pharmaceuticals Holding Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 -62,308.333 101.861 -80,607.449
201612 -34,386.667 101.863 -44,484.824
201703 -22,410.000 102.862 -28,709.328
201706 -18,476.190 103.349 -23,558.232
201709 -11,443.243 104.136 -14,480.611
201712 -10,955.263 104.011 -13,879.701
201803 -14,084.615 105.290 -17,627.751
201806 -11,742.500 106.317 -14,554.445
201809 -9,534.091 106.507 -11,796.124
201812 -11,532.692 105.998 -14,337.400
201903 -4,724.691 107.251 -5,805.118
201906 -1,373.026 108.070 -1,674.220
201909 -1,904.101 108.329 -2,316.224
201912 -6,020.000 108.420 -7,316.842
202003 -2,110.000 108.902 -2,553.204
202006 -891.600 108.767 -1,080.211
202009 -648.850 109.815 -778.610
202012 -357.406 109.897 -428.562
202103 -402.511 111.754 -474.624
202106 -327.808 114.631 -376.836
202109 -303.310 115.734 -345.352
202112 -599.141 117.630 -671.197
202203 -567.646 121.301 -616.666
202206 -300.777 125.017 -317.039
202209 -152.701 125.227 -160.688
202212 -66.652 125.222 -70.141
202303 -106.813 127.348 -110.527
202306 -70.305 128.729 -71.969
202309 -49.292 129.860 -50.020
202312 -11.402 129.419 -11.610
202403 -6.438 131.776 -6.438

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Tonix Pharmaceuticals Holding  (STU:TPM0) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Tonix Pharmaceuticals Holding Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Tonix Pharmaceuticals Holding (STU:TPM0) Business Description

Traded in Other Exchanges
Address
26 Main Street, Suite 101, Chatham, NJ, USA, 07928
Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Tonix Pharmaceuticals Holding (STU:TPM0) Headlines

No Headlines